Australian Biotech CSL Sees Talecris Acquisition As Ticket To Grow Plasma Therapeutics

PERTH, Australia - In what is being called the biggest Australian biotech acquisition, Melbourne-based CSL Limited inked a deal to acquire Talecris Biotherapeutics for $3.1 billion, CSL announced Aug. 13